Researchers develop Rx for deafness, impaired balance in mouse model of Usher syndrome

February 4, 2013

Jennifer Lentz, PhD, Assistant Professor of Otorhinolaryngology & Biocommunications and a member of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, is the lead author of a paper reporting that hearing and balance can be rescued by a new therapy in a mouse model of Usher syndrome (Usher) that contains the mutation responsible for type 1C Usher. The results provide the first evidence that congenital deafness can be effectively overcome by treatment early in development to correct gene expression. The paper, Rescue of hearing and vestibular function in a mouse model of human deafness, is published online February 4, 2013 in Nature Medicine.

Dr. Lentz, along with researchers at Rosalind Franklin University School of Medicine and Science in North Chicago, Illinois and at Isis Pharmaceuticals in Carlsbad, California have developed a novel therapy called an antisense oligonucleotide (ASO) that corrects defective gene expression caused by a mutation in the USH1C gene. Treatment of newborn mice with a single dose of ASOs partially corrects gene and protein expression, and rescues hearing and balance. The results demonstrate the therapeutic potential of ASOs in the treatment of and balance disorders.

Usher syndrome is the leading cause of combined deafness and blindness. Recent estimates suggest that 1 in 6,000 individuals world-wide are affected with Usher. Acadian patients of south Louisiana and Canada have type 1C Usher, the most severe form of the disease. These patients are born deaf, have impaired balance and, when teenagers, become progressively blind.

"Our study demonstrates that a human disease-causing mutations, modeled in mice, can be effectively corrected to treat deafness and balance dysfunction, and that this treatment may need to occur only once in life, during the critical hair cell developmental period," says Dr. Lentz. "Remarkably, deafness and dysfunction are rescued in Usher mice by inducing a relatively small shift in Ush1c gene expression."

Dr. Lentz, who has been studying Usher Syndrome in the Acadian population for the past ten years, led the team of researchers at LSU Health Sciences Center New Orleans which also included Drs. Nicolas G. Bazan, Hamilton E. Farris, and Matthew J. Spalitta. Dr. Michelle L. Hastings, an expert in and targeting, headed the team at Rosalind Franklin University of Medicine and Science, which includes co-lead authors of the paper, Francine M. Jodelka and Anthony J. Hinrich, along with Kate E. McCaffrey and Dominik M. Duelli. Dr. Frank Rigo at Isis Pharmaceuticals specializes in ASO technology and was key to the success of the project.

"Dr. Jennifer Lentz is an exemplary young scientist," notes Dr. Nicolas Bazan, Director of the Neuroscience Center of Excellence, Louisiana State University Center, New Orleans, and one of the co-authors of the paper. "She succeeded in placing the mutation in the type 1 gene (USH1C) responsible for Acadian Usher in a mouse, which opened up the possibility for defining how the disease develops and, more importantly, how it can be cured."

"The discovery of an ASO-type drug that can effectively rescue hearing opens the door to developing similar approaches to target and cure other causes of hearing loss", says Dr. Hastings who will receive a grant from the National Institute of Health to further develop the ASOs for the treatment of deafness with Dr. Lentz and Dr. Duelli.

Explore further: Preclinical development shows promise to treat hearing loss with Usher syndrome III

Related Stories

Preclinical development shows promise to treat hearing loss with Usher syndrome III

July 10, 2012
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North ...

Deafness genetic mutation discovered

September 30, 2012
Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.

Treatment approach to human Usher syndrome: Small molecules ignore stop signals

July 1, 2011
Usher syndrome is the most common form of combined congenital deaf-blindness in humans and affects 1 in 6,000 of the population. It is a recessive inherited disease that is both clinically and genetically heterogeneous. In ...

Biologists achieve repair and read-through of stop mutations responsible for Usher syndrome

December 4, 2012
After years of basic research, scientists at Johannes Gutenberg University Mainz (JGU) are increasingly able to understand the mechanisms underlying the human Usher syndrome and are coming ever closer to finding a successful ...

Gene therapy holds promise for reversing congenital hearing loss

July 25, 2012
A new gene therapy approach can reverse hearing loss caused by a genetic defect in a mouse model of congenital deafness, according to a preclinical study published by Cell Press in the July 26 issue of the journal Neuron. ...

Recommended for you

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

Newly identified genetic marker may help detect high-risk flu patients

July 17, 2017
Researchers have discovered an inherited genetic variation that may help identify patients at elevated risk for severe, potentially fatal influenza infections. The scientists have also linked the gene variant to a mechanism ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.